Research Papers

25 of 947 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus d…
Nagler A; Labopin M; Blaise D; Raiola AM; Corral LL; Bramanti S; Sica S; Kwon M; Koc Y; Pavlu J; Kulagin A; Busca A; Rodríguez AB; Reményi P; Schmid C; Brissot E; Sanz J; Bazarbachi A; Giebel S; Ciceri F; Mohty M.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Gastric cancer treatment: recent progress and future perspectives.
Guan WL; He Y; Xu RH.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute ly…
Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E.
J Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
The Notch signaling pathway: a potential target for cancer immunotherapy.
Li X; Yan X; Wang Y; Kaur B; Han H; Yu J.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Emerging evidence and treatment paradigm of non-small cell lung cancer.
Liu SM; Zheng MM; Pan Y; Liu SY; Li Y; Wu YL.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in l…
Wang D; Li X; Jiao D; Cai Y; Qian L; Shen Y; Lu Y; Zhou Y; Fu B; Sun R; Tian Z; Zheng X; Wei H.
J Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS; Pratz KW; Lai C.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications.
Zhao B; Wu B; Feng N; Zhang X; Zhang X; Wei Y; Zhang W.
J Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH; Wouters AK; Wachsmann TLA; Hagedoorn RS; Kester MGD; Remst DFG; van der Steen DM; de Ru AH; van Hees EP; Kremer M; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM.
J Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.
Zhu XN; Wei YS; Yang Q; Liu HR; Zhi Z; Zhu D; Xia L; Hong DL; Yu Y; Chen GQ.
J Hematol Oncol (Unknown)
Published: 2023
5/6 Transparent
Data Code Funding Declared
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
Li C; Zhou F; Wang J; Chang Q; Du M; Luo W; Zhang Y; Xu J; Tang L; Jiang H; Liu L; Kou H; Lu C; Liao D; Wu J; Wei Q; Ke S; Deng J; Liu C; Mei H; Hu Y.
J Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Li Y; Liu J; Chen W; Wang W; Yang F; Liu X; Sheng Y; Du K; He M; Lyu X; Li H; Zhao L; Wei Z; Wang F; Zheng S; Sui J.
J Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cupr…
Tong X; Tang R; Xiao M; Xu J; Wang W; Zhang B; Liu J; Yu X; Shi S.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis.
Li Z; Zhou Y; Jia K; Yang Y; Zhang L; Wang S; Dong Y; Wang M; Li Y; Lu S; Zhang W; Zhang L; Fan Y; Zhang D; Li N; Yu Y; Cao X; Hou J.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications.
Zhong X; He X; Wang Y; Hu Z; Huang H; Zhao S; Wei P; Li D.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer gro…
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tum…
Beider K; Voevoda-Dimenshtein V; Zoabi A; Rosenberg E; Magen H; Ostrovsky O; Shimoni A; Weiss L; Abraham M; Peled A; Nagler A.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy…
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma.
Liu T; Han C; Fang P; Ma Z; Wang X; Chen H; Wang S; Meng F; Wang C; Zhang E; Dong G; Zhu H; Yin W; Wang J; Zuo X; Qiu M; Wang J; Qian X; Shen H; Xu L; Hu Z; Yin R.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies.
Shi X; Yang J; Deng S; Xu H; Wu D; Zeng Q; Wang S; Hu T; Wu F; Zhou H.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.
Tian H; Zhang T; Qin S; Huang Z; Zhou L; Shi J; Nice EC; Xie N; Huang C; Shen Z.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
ASXL1/2 mutations and myeloid malignancies.
Medina EA; Delma CR; Yang FC.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment m…
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA.
J Hematol Oncol (Unknown)
Published: 2022
5/6 Transparent
Data Registered Funding Declared